

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)

A13

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : C07K 15/28, A61K 39/395 C12P 21/08	A1	(11) International Publication Number: WO 91/05805 (43) International Publication Date: 2 May 1991 (02.05.91)
(21) International Application Number: PCT/US90/06030 (22) International Filing Date: 19 October 1990 (19.10.90) (30) Priority data: 424,883 20 October 1989 (20.10.89) US (71) Applicant: TRUSTEES OF DARTMOUTH COLLEGE [US/US]; 311 McNutt Hall, P.O. Box 7, Hanover, NH 03755 (US). (72) Inventors: SHEN, Li ; Rural Route Box 29, Thetford Center, VT 05075 (US). FANGER, Michael, W. ; Rural Route 1, Box 421, Lebanon, NH 03766 (US).		(74) Agents: DeCONTI, Giulio, A., Jr. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published: <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR (57) Abstract <p>Monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	CA	Osborn	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTORBackground

Receptors for the Fc portion of immunoglobulin are important in triggering many of the protective functions of monocytes, macrophages and polymorphonuclear cells. While receptors for IgG on these cells have been extensively investigated, it is becoming evident that receptors for IgA are also capable of promoting effector functions of these cells and that IgE may stimulate some activities of monocytes. While soluble IgA binds IgA receptor with poor avidity, polymerized IgA has been demonstrated to trigger functions such as superoxide generation and phagocytosis.

Summary of the Invention

This invention pertains to monoclonal antibody which specifically binds to Fc receptor for IgA (Fc-alpha receptor) on an effector cells such as a monocytes, polymorphonuclear cells and macrophages and which can trigger Fc-alpha-receptor-mediated effector function. The antibody (or fragment thereof) can be linked (chemically or genetically) to an antibody (or fragment thereof) specific for a target antigen to form a bispecific antibody or heteroantibody. These bispecific molecules can be used direct effector cells to cell bearing the target antigen, resulting in cytolysis of the cell.

Detailed Description of the Invention

The antibody of this invention binds the Fc-alpha receptor (FcRI) for human IgA. The monoclonal

-2-

anti-Fc-alpha receptor antibody of this invention can be produced by conventional monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975). Although
05 somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibody can be employed e.g., viral or oncogenic transformation of B lymphocytes.

Human cells bearing Fc-alpha receptor can be used
10 to immunize an animal for production of monoclonal antibody. Alternatively, the receptor for immunization of an animal can be prepared from lysates of human cells which express the receptor, e.g., a human monocytic cell. In another mode, a partially purified
15 preparation of the receptor can be made by lysing receptor-bearing cells and then purifying the receptor by immunoadsorbant chromatography. Cells can be lysed in a buffer containing a detergent such as NP40. The immunoadsorbent can be prepared by attaching human IgA
20 to a water-insoluble material such as an activated SepharoseTM resin. The Sepharose resin with attached human IgA is poured into a column. The cell lysate is passed through the column under conditions which permit adsorption of the cellular Fc receptor protein
25 by the IgA coupled to the resin. The adsorbed Fc receptor protein can be eluted with a mildly acidic elution buffer. The purified receptor can then be used for immunization of an animal to produce anti-receptor monoclonal antibody.

30 The preferred animal system for preparing hybridomas is the murine system. Hybridoma production in the mouse is a very well-established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are well known in the art. Fusion

-3-

partners (e.g., murine myeloma cells) and fusion procedures are also well-known.

Employing the methodology described, a monoclonal antibody (mAb) My 43 of the IgM class which binds specifically to monocyte and polymorphonuclear cell IgA receptors, based on its ability to block IgA mediated rosettes and phagocytosis. This antibody recognizes a surface molecule which triggers function since monocytes and PMNs secrete superoxide when treated with this antibody. Additional technical information on My 43 is reported in Shen, L., Immunology 68:491-496 (1989) and Shen, L. et al., J. Immunol. 143(12):4117-4122 (1989).

The antibodies of this invention can be used to target effector cells bearing Fc-alpha receptor. To target effector cells, bifunctional antibodies or hetero-antibodies are employed. These antibodies have dual antigen binding specificity - one specificity for the Fc-alpha receptor and one specificity for an epitope of the target cell. The Fc receptor specificity mediates linkage to the effector cell through a known cytotoxic trigger molecule. The target cell specificity provides for recognition and binding to the target cell.

Bifunctional antibodies are single, divalent antibodies which have two different antigen binding sites. Bifunctional antibodies for targeting have one binding site for Fc receptor and one binding site for a target cell epitope.

Heteroantibodies are two or more antibodies or antibody binding fragments (Fab) linked together, each antibody or fragment having a different specificity. Heteroantibodies for targeting comprise an antibody or antigen binding fragment specific for Fc receptor for IgA, coupled to an antibody or antigen binding fragment thereof specific for a target cell epitope.

-4-

Bifunctional antibodies can be produced by chemical techniques (see e.g., D. M. Kranz et al., Proc. Natl. Acad. Sci. USA 78,5807 (1981)) by "polydome" techniques (See U.S. Patent 4,474,893, to Reading) or by recombinant DNA techniques. Heteroantibodies can be prepared by conjugating Fc receptor antibody with antibody specific for an epitope of a target cell. A variety of coupling or crosslinking agents can be used to conjugate the antibodies. Examples are protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). SPDP is the preferred agent; procedures for crosslinking antibodies with this agent are known in the art. See e.g., Karpovsky et al., (1984) J. Exp. Med. 160:1686; Liu, M.A. et al., (1985) Proc. Natl. Acad. Sci USA 82:8648.

Employing the SPDP agent, bi-specific antibodies of the monoclonal antibody My 43 and Fab anti-erythrocyte antibodies were prepared and shown to promote phagocytosis by monocytes (whereas bi-specific antibodies of anti-RBC x-anti-beta₂ microglobulin did not). In comparative studies on phagocytosis, an average of 52% of monocytes ingested IgKG coated red cells and 32% ingested cells coated with My 43 bi-specific antibodies.

Target cells are cells whose elimination would be beneficial to the host. One important type of cell is a tumor cell. Effector cells can be targeted with bifunctional or heteroantibody having specificity for FcRI and specificity for a tumor associated or tumor specific antigen.

Antibodies with a desired tumor specificity for production of bifunctional antibody or heteroantibody can be produced or can be selected from available sources. Monoclonal antibodies against

-5-

tumor-associated antigens can be made by the methods of Koprowski et al., U.S. Patent 4,172,124. Many suitable anti-cancer antibodies are presently available.

Specific anti-tumor antibodies would include, but
05 not be limited to:

<u>Antibody</u>	<u>Specificity</u>
AML-2-23, PM-81, PMN-6, PMN-19	Myeloid Leukemia
SCCL-1, SCCL-175	Small Cell Carcinoma of the Lung
OC1-25, OVCT-3	Ovarian Carcinoma
COL-1, COL-2, COL-3, ... COL-13	Colon Carcinoma

In addition to tumor cells, the effector cell can be targeted against auto-antibody producing lymphocyte for treatment of autoimmune disease or an IgE-producing lymphocyte for treatment of allergy. The target can also
10 be microorganism (bacterium or virus) or a soluble antigen (such as rheumatoid factor or other auto-antibodies).

Effector cells for targeting are human leukocytes, preferably macrophages. Other cells would include
15 monocytes and other IgA-receptor bearing cells. If desired, effector cells for targeting can be obtained from the host to be treated.

The targeted effector cells can be administered as a suspension of cells in a physiologically acceptable
20 solution. The number of cells administered can be in the order of 10^8 - 10^9 but will vary depending on the therapeutic purpose. In general, the amount will be sufficient to obtain localization at the target cell and to effect target cell killing by antibody dependent mediated
25 cytolysis (ADCC). Routes of administration can

-6-

also vary. In tumor therapy, for instance, depending upon the localization of a tumor, the targeted effector cells could be administered intravenously, or directly into tumor sites; as for example, directly into the
05 peritoneal cavity in the case of ovarian carcinoma.

Therapy with targeted effector cells can be performed in conjunction with other techniques for removal of targeted cells. For example, anti-tumor therapy with bifunctional antibodies and/or effector
10 cells armed with bifunctional (hetero)antibody can be used in conjunction with surgery, chemotherapy or radiotherapy. Additionally, combination immunotherapy may be used to direct two distinct cytotoxic effector populations toward tumor cell rejection. For example, anti-
15 tumor antibodies linked to anti-Fc-gammaRI or anti-T3 (will trigger cytolytic T lymphocytes to lyse tumor cells) may be used in conjunction with IgA-receptor specific heteroantibodies. Protocols based on these concepts may be especially effective in removing residual
20 tumor cells in patients induced into remission by chemotherapy and irradiation.

The anti-Fc-alpha receptor antibody of this invention has additional utility in therapy and diagnosis. The Fc receptor antibody itself can be a
25 targeting antibody (i.e., to target for cells bearing Fc-alpha receptor). For example, the antibody can be used to target lipid vesicles containing anticancer drugs for treatment of certain hematological cancers (e.g. acute myeloid leukemia), or to target lipid vesicles
30 containing factors (such as gamma-IFN) which activate monocytes. The antibody, if of the appropriate murine IgG subclass (e.g., IgG2a), can be used directly in vivo to eliminate Fc-alpha-receptor-bearing cells (e.g.,

-7-

myeloid leukemia cells) via natural complement or ADCC mechanisms.

Equivalents

05 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

-8-

CLAIMS

1. A monoclonal antibody specific for human IgA receptor.
2. Monoclonal anti-Fc-alpha antibody My 43.
- 05 3. A bifunctional antibody or heteroantibody, comprising:
 - a. at least one antigen binding region derived from an human anti-Fc-alpha receptor antibody; and
 - 10 b. at least one antigen binding region specific for a target epitope.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 90/06030

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 K 15/28, A 61 K 39/395, C 12 P 21/08		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 07 K; A 61 K; C 12 P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Monogr. Allergy, Vol. 24, 1988, Hidekado Tokumoto et al.: "Monoclonal Antibody (G6) Inhibiting IgA Binding to Fixed Fc R(+) T2D4 Cells ", see page 208 - page 214 see pages 209-211	1
Y	--	1, 3
Y	Immunology, Vol. 64, 1988, M. Albrechtsen et al.: "Characterization of the IgA receptor from human polymorphonuclear leucocytes ", see page 201 - page 205 see page 204, left col. and "DISCUSSION"	1
A	FASEB J., Vol. 3, February 1989, R.C. Monteiro et al.: "Molecular characterization of IgA receptor on human monocytes and monocytic cell line U937 ", see page A110	1
	--	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>^A document defining the general state of the art which is not considered to be of particular relevance</p> <p>^B earlier document but published on or after the international filing date</p> <p>^C document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>^O document referring to an oral disclosure, use, exhibition or other means</p> <p>^P document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>^T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>^X document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>^Y document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>^S document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
4th February 1991	19. 02. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	<div style="display: flex; align-items: center;"> <div style="border: 1px solid black; padding: 2px 5px; margin-right: 10px;">M. PRIS</div> <div style="font-family: cursive; font-size: 1.2em;">M. PRIS</div> </div>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Immunology, Vol. 68, 1989, L. Shen et al.: "Monocyte superoxide secretion triggered by human IgA ", see page 491 - page 496 see page 492, left col. last paragraph and page 495, left col. second paragraph --	1,3
A	The Journal of Immunology, Vol. 142, No. 7, April 1989, Alain Chevaillier et al.: "Immunofluorescence analysis of IgA binding by human mononuclear cells in blood and lymphoid tissue ", see page 2244 - page 2249 --	1
P,X	The Journal of Immunology, Vol. 143, December 1989, Li Shen et al.: "My 43. A monoclonal antibody that reacts with human myeloid cells inhibits monocyte IgA binding and triggers function ", see page 4117 - page 4122 see the whole document -- -----	1-3